Myocardial fibrosis in hypertrophic cardiomyopathy

New England Journal of Medicine

Volumn 363, Issue 20, 2010, Pages 1971-

  Kaye, David M ^a   Iles, Leah ^a   Taylor, Andrew J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; PROPEPTIDE OF TYPE I COLLAGEN; UNCLASSIFIED DRUG;

DIASTOLIC DYSFUNCTION; DISEASE MARKER; GENOTYPE PHENOTYPE CORRELATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LETTER; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; REST;

EID: 78149474695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1010535     Document Type: Letter

References (4)

1. Ho CY, López B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-63.
2. Esler M, Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev 2000;5:17-25. (Pubitemid 30301508)
3. Choi EY, Ha JW, Rim SJ, et al. Incremental value of left ventricular diastolic function reserve index for predicting exercise capacity in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2008;21:487-92.
4. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008;52:1574-80.